(Infocast News) SINO BIOPHARM (01177) bought back 4M shares at between HK$3.19 and HK$3.42 per share, or a total of about HK$13.37M on April 9.
Total share repurchased in the current fiscal year is 4M.
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
(Infocast News) SINO BIOPHARM (01177) bought back 5M shares at between HK$3.32 and HK$3.42 per share, or a total of about HK$17M on April 8.
Total share repurchased in the current fiscal year is 5M.
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
SINO BIOPHARM (01177) FY24 profit up 50%; div $0.04
SINO BIOPHARM (01177) FY24 profit up 50%; div $0.04
Result Ann
SINO BIOPHARM (01177) FY24 profit up 50%; div $0.04
(Infocast News) Results of Sino Biopharmaceutical Limited (01177) for the fiscal year ended 31 December 2024:
Net profit: RMB3.4998B, up 50.08% YoY (RMB2.3319B net profit for the same period last year) Basic EPS: RMB0.1913 Dividend per share proposed: HK$0.04
(JJ)
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
SINO BIOPHARM (01177) posts a block trade for $34.32M
SINO BIOPHARM (01177) posts a block trade for $34.32M
Market Talk
SINO BIOPHARM (01177) posts a block trade for $34.32M
(Infocast News)
Stock name : SINO BIOPHARM (01177)
Block trade : 1 deal
Price : HK$3.426
Qty : 10.02M
Turnover : $34.32M
Time Price Qty Turnover
--------------------------------------------------
09:00:00 3.426 10,018,800 34,324,409
* Block Trade: Turnover per trade > HKD $20 million
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
(Infocast News) SINO BIOPHARM (01177) bought back 3.5M shares at between HK$2.79 and HK$2.81 per share, or a total of about HK$9.83M on January 16. Total share repurchased in the current fiscal year is 3.5M.
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
(Infocast News) SINO BIOPHARM (01177) bought back 5M shares at between HK$2.85 and HK$2.89 per share, or a total of about HK$14.37M on January 14. Total share repurchased in the current fiscal year is 5M.
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
(Infocast News) SINO BIOPHARM (01177) bought back 7M shares at between HK$2.85 and HK$2.92 per share, or a total of about HK$20.12M on January 10. Total share repurchased in the current fiscal year is 7M.
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
(Infocast News) SINO BIOPHARM (01177) bought back 6M shares at between HK$2.95 and HK$3.00 per share, or a total of about HK$17.93M on January 8. Total share repurchased in the current fiscal year is 6M.
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
SINO BIOPHARM (01177) 1H profit up 140%; div $0.03
SINO BIOPHARM (01177) 1H profit up 140%; div $0.03
Result Ann
SINO BIOPHARM (01177) 1H profit up 140%; div $0.03
(Infocast News) Results of Sino Biopharmaceutical Limited (01177) for the first half-year ended 30 June 2024:
Net profit: RMB3.0172B, up 139.69% YoY (RMB1.2588B net profit for the same period last year) Basic EPS: RMB0.1639 Dividend per share proposed: HK$0.03
(WL)
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Tse, Theresa Y Y (Chairman and Executive Director)
Tse Ping (Senior Deputy Chairman and Executive Director)
Cheng Cheung Ling (Vice Chairman and Executive Director)
Tse Hsin (Vice President and Executive Director)
Tse, Eric S Y (Chief Executive Officer and Executive Director)
Tian Zhoushan (Executive Director)
Li Dakui (Independent Non-Executive Director)
Lu Zhengfei (Independent Non-Executive Director)
Lu Hong (Independent Non-Executive Director)
Zhang Lu Fu (Independent Non-Executive Director)
LI Kwok Tung Donald (Independent Non-Executive Director)
Secretary
Chan Oi Nin Derek
Auditor
Ernst & Young
Address
Unit 09, 41st Floor, Office Tower, Convention Plaza, 1 Harbour Road, Wanchai, Hong Kong
Principally engaged in the research and development, production and sale of a series of modernised Chinese medicines and chemical medicines.
Prospects
In the global pharmaceutical industry structure, the Chinese pharmaceutical market has occupied a key position due to its huge volume, stable and increasing market demand, and strong innovation drivers.Its role in the global pharmaceutical development process has become increasingly prominent, and its influence on the global pharmaceutical industry is growing.
As a strategic industry closely linked to the national economy and people's livelihood, the pharmaceutical industry receives key support from national policies and incentives. In January 2025, the National Healthcare Security Administration announced that it would release the first edition of the Category C of NRDL within a year. As a supplement to the current Category A and B of NRDL, the Category C focuses on drugs that are not yet covered by medical insurance because they are beyond the'basic insurance coverage', but are highly innovative, have significant clinical value, and can greatly benefit patients. At the same time, the National Healthcare Security Administration will introduce incentives to facilitate the inclusion of Category C drugs within the coverage scope of affordable commercial health insurance, so as to realize the effective connection between the Category C and the basic medical insurance directory. This series of policies is expected to broaden the pricing flexibility of innovative drugs, improve their accessibility, and create a wider market prospect for such drugs.
The Group has closely followed national, social and industry development trends and continuously optimized its development strategy.
Principal Bankers
Agricultural Bank of China Limited
Bank of China (Hong Kong) Limited
The HongKong and Shanghai Banking Corporation Limited
Registry
Tricor Investor Services Ltd.
17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong
Major Shareholders
Tse, Eric S Y (21.60%)
Cheng Cheung Ling (15.82%)
Tse Ping (8.84%)
Share Placement
Announcement Date
No. of Placing Shares
Price ($)
Announcement Date
N/A
No. of Placing Shares
N/A
Price ($)
N/A
Share Repurchase
Repurchase Date
Repurchase Amount
Highest Price ($)
Lower Price ($)
Repurchase Date
2025-04-09
Repurchase Amount
4,000,000
Highest Price ($)
3.420
Lower Price ($)
3.190
Repurchase Date
2025-04-08
Repurchase Amount
5,000,000
Highest Price ($)
3.420
Lower Price ($)
3.320
Repurchase Date
2025-01-16
Repurchase Amount
3,500,000
Highest Price ($)
2.810
Lower Price ($)
2.790
Repurchase Date
2025-01-14
Repurchase Amount
5,000,000
Highest Price ($)
2.890
Lower Price ($)
2.850
Repurchase Date
2025-01-10
Repurchase Amount
7,000,000
Highest Price ($)
2.920
Lower Price ($)
2.850
Financial Record
Profit & Loss Account
2024-12-31 (HK$M)
2023-12-31 (HK$M)
2022-12-31 (HK$M)
2021-12-31 (HK$M)
Turnover
Operating Profit
Exception Items
Pre-Tax Profit / Loss
Net Profit / Loss
Earnings Per Share (¢)
Dividend Per Share (¢)
P / E (x)
Dividend Yield (%)
2024-12-31 (HK$M)
Turnover
30,755.83
Operating Profit
7,878.19
Exception Items
N/A
Pre-Tax Profit / Loss
7,438.52
Net Profit / Loss
3,722.07
Earnings Per Share (¢)
20.35
Dividend Per Share (¢)
7.00
P / E (x)
15.73
Dividend Yield (%)
2.19
2023-12-31 (HK$M)
Turnover
30,842.09
Operating Profit
7,682.72
Exception Items
N/A
Pre-Tax Profit / Loss
6,539.99
Net Profit / Loss
2,570.26
Earnings Per Share (¢)
13.87
Dividend Per Share (¢)
5.00
P / E (x)
25.01
Dividend Yield (%)
1.44
2022-12-31 (HK$M)
Turnover
32,268.60
Operating Profit
7,142.76
Exception Items
N/A
Pre-Tax Profit / Loss
6,478.97
Net Profit / Loss
2,851.85
Earnings Per Share (¢)
15.31
Dividend Per Share (¢)
12.00
P / E (x)
29.84
Dividend Yield (%)
2.63
2021-12-31 (HK$M)
Turnover
32,854.12
Operating Profit
6,421.89
Exception Items
N/A
Pre-Tax Profit / Loss
22,716.24
Net Profit / Loss
17,867.55
Earnings Per Share (¢)
95.20
Dividend Per Share (¢)
8.00
P / E (x)
5.74
Dividend Yield (%)
1.47
Balance Sheet
2024-12-31 (HK$M)
2023-12-31 (HK$M)
2022-12-31 (HK$M)
2021-12-31 (HK$M)
Current Assets
Non-current Assets
Total Assets
Current Liabilities
Non-current Liabilities
Total Liabilities
Total Equity
2024-12-31 (HK$M)
Current Assets
26,252.85
Non-current Assets
43,308.63
Total Assets
69,561.48
Current Liabilities
20,798.33
Non-current Liabilities
3,272.93
Total Liabilities
24,071.26
Total Equity
45,490.22
2023-12-31 (HK$M)
Current Assets
26,238.46
Non-current Assets
43,866.78
Total Assets
70,105.23
Current Liabilities
24,917.19
Non-current Liabilities
3,117.12
Total Liabilities
28,034.31
Total Equity
42,070.92
2022-12-31 (HK$M)
Current Assets
29,078.22
Non-current Assets
42,750.66
Total Assets
71,828.88
Current Liabilities
22,592.94
Non-current Liabilities
6,693.63
Total Liabilities
29,286.57
Total Equity
42,542.31
2021-12-31 (HK$M)
Current Assets
28,746.74
Non-current Assets
45,303.82
Total Assets
74,050.56
Current Liabilities
18,768.49
Non-current Liabilities
9,135.69
Total Liabilities
27,904.19
Total Equity
46,146.37
Financial Ratios
2024-12-31
2023-12-31
2022-12-31
2021-12-31
Return On Asset (ROA)
Return On Equity (ROE)
Net Profit Margin
Gross Profit Margin
Debt To Equity Ratio
Asset To Equity Ratio
Current Ratio (x)
P / E (x)
Dividend Yield (%)
2024-12-31
Return On Asset (ROA)
5.35
Return On Equity (ROE)
8.18
Net Profit Margin
12.10
Gross Profit Margin
25.62
Debt To Equity Ratio
52.92
Asset To Equity Ratio
152.92
Current Ratio (x)
1.26
P / E (x)
15.73
Dividend Yield (%)
2.19
2023-12-31
Return On Asset (ROA)
3.67
Return On Equity (ROE)
6.11
Net Profit Margin
8.33
Gross Profit Margin
24.91
Debt To Equity Ratio
66.64
Asset To Equity Ratio
166.64
Current Ratio (x)
1.05
P / E (x)
25.01
Dividend Yield (%)
1.44
2022-12-31
Return On Asset (ROA)
3.97
Return On Equity (ROE)
6.70
Net Profit Margin
8.84
Gross Profit Margin
22.14
Debt To Equity Ratio
68.84
Asset To Equity Ratio
168.84
Current Ratio (x)
1.29
P / E (x)
29.84
Dividend Yield (%)
2.63
2021-12-31
Return On Asset (ROA)
24.13
Return On Equity (ROE)
38.72
Net Profit Margin
54.38
Gross Profit Margin
19.55
Debt To Equity Ratio
60.47
Asset To Equity Ratio
160.47
Current Ratio (x)
1.53
P / E (x)
5.74
Dividend Yield (%)
1.47
Dividend History
Dividend History
Year End:
2024-12-31
Announce Date
Ex-Date
Payable Date
Amount (¢)
Type
Announce Date
N/A
Ex-Date
2025-06-16
Payable Date
2025-07-10
Amount (¢)
4.00
Type
Final
Announce Date
N/A
Ex-Date
2024-09-10
Payable Date
2024-10-04
Amount (¢)
3.00
Type
Interim
Announce Date
N/A
Ex-Date
2024-06-11
Payable Date
2024-07-05
Amount (¢)
3.00
Type
Final
Announce Date
N/A
Ex-Date
2023-10-04
Payable Date
2023-10-27
Amount (¢)
2.00
Type
Interim
Announce Date
N/A
Ex-Date
2023-06-20
Payable Date
2023-07-18
Amount (¢)
6.00
Type
Final
Announce Date
N/A
Ex-Date
2022-09-06
Payable Date
2022-09-28
Amount (¢)
6.00
Type
Interim
Announce Date
N/A
Ex-Date
2022-06-15
Payable Date
2022-07-12
Amount (¢)
4.00
Type
Final
Capital Changes
Ex-Date
Type
Ex-Date
N/A
Type
N/A
Description
Description
N/A
App Download
Instant trading of stocks after taking an in-depth look at every move of the market
Website Push Notifications
Provide the latest financial news and promotions
Subscribe to keep up to date with CHIEF
Informative contents include:
Latest news, coming seminar, featured articles on wealth management
Stock Information Provided by Infocast Limited
1
